TMCnet

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

The study is led by Professor Shen Lin of Peking University Cancer Hospital. In the safety run-in stage, Opamtistomig in combination with chemotherapy demonstrated encouraging efficacy signals in ...
The Manila Times

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) today announced the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) ...
TMCnet

Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow-Up Shows Continued Efficacy Improvement

Importantly, the abstract data reflect only 3.6 months of median follow-up at the time of data cutoff, and updated results based on more than 7 months of follow-up, to be presented at WCLC are ...